Navigation Links
Market testing of dietary supplements and drugs underscores value of USP's public health programs
Date:11/12/2007

Rockville, Md., November 12, 2007 On September 10, 2007, ConsumerLab.com issued a report stating that several multivitamin supplements did not contain label amounts of folic acid. One of these products, B-50 Tablets, manufactured by IVC, Industries, Inc., is part of U. S. Pharmacopeias (USP) Dietary Supplement Verification Program and carries the USP Verified mark. In response to the report, USP studied the verified product to confirm the announced results. USPs testing found that the B-50 Tablets do in fact contain the required amount of folic acid, as claimed on the products label. The testing also demonstrated that the tablet in question meets USP dissolution requirements. USPs analysis showed that using appropriate test methods for the type of material under assessment, as provided in the United States Pharmacopeia and National Formulary (USPNF), is key to getting accurate results.

The importance of ongoing testing of dietary supplements to a public monograph is hard to overstate, said Roger L. Williams, M.D., executive vice president and CEO of USP. For this reason, USP acknowledges ConsumerLab.coms marketplace surveillance efforts. At the same time, these efforts require careful follow-up, which USP was able to do via its USP Verified agreement with the manufacturer of the B-50 Tablets. USP understands that further studies may be conducted by manufacturers and the Food and Drug Administration (FDA) based on the September 10 report.

The USP Verified program for dietary supplements and their ingredients provides a rigorous array of tests, resulting in manufacturer and consumer confidence that whats on the label is whats in the bottle. Via its voluntary, fee-based agreements with manufacturers, USP has a continuing commitment to monitor the quality of verified ingredients and products. USP was pleased to be able to clarify some of the findings of ConsumerLab.com.

In a separate report dated Oct
'/>"/>

Contact: Sandra Kim
sek@usp.org
301-816-8241
US Pharmacopeia
Source:Eurekalert

Page: 1 2

Related biology news :

1. New study warns limited carbon market puts 20 percent of tropical forest at risk
2. Emerging (disease) markets
3. M2SYS Partners with SecuGen Corporation to Support Market Leading Hamster Plus Fingerprint Reader with Auto-On Technology
4. IEEE-USA innovation forum will help prepare US tech leaders to prosper in a global marketplace
5. Ceres and Texas A&M to develop and market high-biomass sorghum for biofuels
6. Safe water: simpler method for analyzing radium in water samples cuts testing time
7. Genetic ancestral testing cannot deliver on its promise, study warns
8. ACT Ensures Integrity of Testing Process Through Deployment of BIO-keys(R) Biometric ID Technology
9. UF scientists reveal how dietary restriction cleans cells
10. Dietary calcium could possibly prevent the spread of breast cancer to bone
11. Changing the global dietary environment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... julio de 2015 BGI llevará a cabo la ... 22 al 25 de octubre de 2015, en ... celebra su décimo aniversario este año. Desde su inauguración ... las reuniones anuales más influyentes del mundo en los ... conferencias científicas más dinámicas, entusiastas y amenas. ...
(Date:7/31/2015)... Chine, 31 juillet 2015 La 10e ... ) sera organisée par le BGI du 22 ... en Chine. La conférence ... inauguration en 2006, l,ICG est devenue l,une des ... domaine des « omiques » et c,est aussi la plus ...
(Date:7/31/2015)... SHENZHEN, China , 31. Juli 2015 Die ... ) wird von BGI veranstaltet und findet vom ... Shenzhen, China , statt. ... Jubiläum. Seit ihrem Start 2006 ist die ICG ... Bereich „omik" geworden. Sie ist eines der dynamischsten, ...
Breaking Biology News(10 mins):La 10ª Conferencia Internacional sobre Genómica (ICG-10) comienza en octubre 2La 10ª Conferencia Internacional sobre Genómica (ICG-10) comienza en octubre 3La 10e International Conference on Genomics (ICG-10) doit s'ouvrir en octobre 2La 10e International Conference on Genomics (ICG-10) doit s'ouvrir en octobre 3Die 10. internationale Konferenz zu Genomik (ICG-10) beginnt im Oktober 2Die 10. internationale Konferenz zu Genomik (ICG-10) beginnt im Oktober 3
... has provided the first detailed look at the internal head ... fossil animal that represents an important intermediate step in the ... Results of the study, published in this week,s issue ... from aquatic to terrestrial lifestyle involved complex changes not only ...
... dine on fish, shrimp, and mollusks, they are ... New genetic research carried out by Eugenia Naro-Maciel, ... Biodiversity and Conservation at the American Museum of ... the evolutionary relationships among all seven sea turtle ...
... of cells can be detected in a mineral likely ... obtained using a technique developed at the U.S. Department ... choose Martian surface samples with the most promise for ... tiny bits of mineral and looks for chemical signatures ...
Cached Biology News:Details of evolutionary transition from fish to land animals revealed 2Revealing the evolutionary history of threatened sea turtles 2Sensitive laser instrument could aid search for life on Mars 2Sensitive laser instrument could aid search for life on Mars 3
(Date:7/30/2015)... ... July 30, 2015 , ... Tronics, ... as Sales & Marketing Director. , With more than 25 years of ... for reinforcing Tronics’ business development activities worldwide. He brings to the company his ...
(Date:7/30/2015)... -- According to a new market research ... PKPD, Trial Design, Toxicity Prediction, In-house, Contract Service), by ... End Users - Global Forecast to 2020", published by ... 2,107.99 million by 2020 from USD 1,034.93 million in ... Browse more than 75 market ...
(Date:7/30/2015)... 30, 2015   Aratana Therapeutics, Inc . ... focused on the licensing, development and commercialization of ... that its strategic partner VetStem Biopharma, Inc. has ... of AT-016, an adipose-derived allogeneic stem cell product ... osteoarthritis pain in dogs. The double-blinded, ...
(Date:7/30/2015)... 2015  With over 60,000 customers across the globe, ISN improves the efficiency and ... with more than 60,000 safe and reliable contractors in over 80 countries. ... ... Over 60,000 Worldwide Customers ... Headquartered in Dallas, TX , ISN has ...
Breaking Biology Technology:Tronics appoints Francois Vieillard as Sales and Marketing Director 2Biosimulation Market Worth 2,107.99 Million USD by 2020 2Biosimulation Market Worth 2,107.99 Million USD by 2020 3Biosimulation Market Worth 2,107.99 Million USD by 2020 4Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 2Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 3Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 4Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 5ISN Reaches Over 60,000 Worldwide Customers 2ISN Reaches Over 60,000 Worldwide Customers 3
... TO339 transmitted at 1617e today, an error occurred in the first,paragraph. The timing of ... MDT" and not "9:00 pm MDT". Corrected copy follows: ... & Webcast ... RVX, CALGARY, May 1 /PRNewswire-FirstCall/ - Resverlogix Corp.,("Resverlogix") (TSX:RVX) is pleased to announce ...
... of HER1, HER2 and HER3 Assays to Provide Unique ... Facilitate Development of Personalized Cancer Therapies, SOUTH SAN ... ) today announced that the company,s HER1,and HER3 Quantitative ... on Monogram,s VeraTag(TM) platform, the HER1 and,HER3 assays provide ...
... 1 /PRNewswire-FirstCall/ - Resverlogix Corp.,("Resverlogix") (TSX:RVX) is pleased ... on May 8, 2008 at 9:00 pm MDT ... and the business aspects of the Company. Following ... answer session., The webcast can be accessed ...
Cached Biology Technology:/C O R R E C T I O N from Source -- Resverlogix Corp./ 2HER1 and HER3 VeraTag(TM) Assays are Now Available for Use in Development and Clinical Evaluation of Cancer Therapeutics 2HER1 and HER3 VeraTag(TM) Assays are Now Available for Use in Development and Clinical Evaluation of Cancer Therapeutics 3HER1 and HER3 VeraTag(TM) Assays are Now Available for Use in Development and Clinical Evaluation of Cancer Therapeutics 4HER1 and HER3 VeraTag(TM) Assays are Now Available for Use in Development and Clinical Evaluation of Cancer Therapeutics 5Resverlogix Notice of Conference Call & Webcast 2